Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: KuicK Research | PRODUCT CODE: 1075418

Cover Image

PUBLISHER: KuicK Research | PRODUCT CODE: 1075418

Global CAR T Cell Therapy Market & Clinical Trials Insight 2028

PUBLISHED:
PAGES: 720 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 3000
PDF (Multi-User License)
USD 6000

Add to Cart

Global CAR T Cell Therapy Market & Clinical Trials Insight 2028 Report Highlights:

  • Research Methodology
  • Global CAR T Cell Therapy Market Opportunity > USD 15 Billion
  • Global & Regional Market Insight: Current & Market Forecast 2028
  • Approved CAR T Cell Therapies Sales Forecast Till 2028
  • Emerging In Vivo Induced CAR T Cell Therapies
  • CAR T Cell Therapy Manufacturing Cost Analysis
  • CAR T Cell Therapy Approval & Reimbursement Scenario By Country
  • Patent, Price, Sales Insight On 6 Approved CAR T Cell Therapies
  • Insight On More Than 600 CAR T Cell Therapies In Clinical Trials
  • CAR T Cell Therapies Clinical Trials Insights by Company, Country & Phase

Chimeric antigen receptor (CAR) T cell therapy is novel immunotherapeutic approach which is indicated for the management of cancer. CAR T-cell therapy is a type of therapy in which the T-cells are taken from the blood of the patient, which is then modified in a lab by the addition of a gene for a man-made receptor (chimeric antigen receptor). This aids in better recognizing of specific cancer cell antigens. The CAR T-cells are then given back to the patient. To date, 6 CAR T-cell therapy products including Kymriah (tisagenlecleucel), yescarta (axicabtagene), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), and Abecma (idecabtagene vicleucel) have been approved by FDA for the management of wide range of cancers. In addition to this, Relmacabtagene autoleucel have been approved in China.

The introduction of CAR T cell therapies have shown high adoption rates in short span of time has propelled the further research and development activities in this domain. Apart from hematological malignancies, the researchers are also expanding the role of CAR T cell therapies in solid tumors which will propel the growth of market. For instance, a recent research study demonstrated that infusing immune cells into patients has shown early promise by shrinking tumors in digestive system. The interim results demonstrated that tumors in nearly 50% of the 37 patients so far reduced in size after the therapy.

The global CAR T cell therapy market is highly consolidated with several key players. The pharmaceutical giants in the market are increasingly partnering or collaborating with technologies companies to integrate advanced technologies for the betterment of CAR-T therapy or to expand geographical presence. For instance, Bayer and Atara Biotherapeutics entered into worldwide license agreement for the development of next generation ATA3271 which is mesothelin-directed CAR-T cell therapy. The agreement also aims to develop ATA2271, for the management of high mesothelin-expressing tumors such as malignant pleural mesothelioma and non-small-cell lung cancer.

Among drug type, Yescarta is currently dominating the market. Yescarta (axicabtagene ciloleucel) is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma. Recently in 2022, regulatory bodies expanded the approval of drug for the management of large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within a year of first-line chemotherapy. The wide range of therapeutic indications as well as global availability of the drug is the major factors which are the major factors aiding in dominance of these factors.

As per our report findings, the Global CAR T cell therapy market opportunity is expected to surpass US$ 15 Billion by 2028. The development of CAR T cell therapy will gather momentum from the increasing number of investors, designers, and analysts in the guide therapy. Rising frequencies of cancer across the globe together with the relentless technological advancement for dependable and effective cancer treatment is expected to support growth of the worldwide CAR-T cell therapy market. Furthermore, heavy investments on clinical research and development in cell therapy are estimated to boost the market for CAR-T cell therapy in the years to come.

Our report provides information on the globally approved CAR T cell therapies along with their price, dosage, and sales analysis. The report analyzes and forecasts the size of the global CAR-T cell therapy market. The report delivers a full-scale exploration of market dynamics and factors that are manipulating the growth of the global CAR-T cell therapy market. The report also gives competitive analysis of major market players will give a competitive advantage to customers in their respective businesses.

Table of Contents

1. Research Methodology

2. Chimeric Antigen Receptor (CAR) T Cell Therapy - Next Era in Immuno Oncology

3. Evolution of Chimeric Antigen Receptor (CAR) T-Cell Design

3.1 Structure of CAR-T Cell

3.2 1st Generation Chimeric Antigen Receptor

3.3 2nd & 3nd Generation CAR-T Cell

3.4 Principle of Chimeric Antigen Receptor Design

4. Approaches to Improve the Efficacy of CAR-T Cell Therapy

5. CAR T Cell Therapy Manufacturing Cost Analysis

6. Emerging In-Vivo Induced CAR T Cell Therapies

6.1 Need of In-Vivo CAR T Cell Therapy

6.2 In-Vivo CAR T Cell Platform; VivoVec, TumorTag, & RACR/CAR

6.3 Key Drug in Research & Development

7. Global CAR T Cell Therapy Market Oulook 2022 - 2028

7.1 Market Overview

7.2 Future Market Opportunity

8. Globally Approved CAR T Cell Therapies - Pricing, Dosage & Sales Analysis 2028

8.1 Tisagenlecleucel (Kymriah)

8.2 Axicabtagene Ciloleuce (Yescarta)

8.3 Brexucabtagene Autoleucel (Tecartus)

8.4 Lisocabtagene maraleucel (Breyanzi)

8.5 Idecabtagene Vicleucel (Abecma)

8.6 Relmacabtagene autoleucel (Carteyva)

8.7 Ciltacabtagene autoleucel (Carvykti)

9. US CAR T Cell Therapy Market Outlook

9.1 Approved & Key CAR T Cell Therapy Products in US

9.2 Market Overview

9.3 Current Reimbursement Scenario

10. Europe CAR T Cell Therapy Market Outlook

10.1 Approved & Key CAR T Cell Therapy Products in Europe

10.2 UK

10.3 Germany

10.4 Spain

10.5 France

10.6 Rest of Europe

10.7 Current Reimbursement Scenario

11. China CAR T Cell Therapy Market Outlook

11.1 Approved & Key CAR T Cell Therapy Products in China

11.2 Current Market Size & Forecast

12. Japan CAR T Cell Therapy Market Outlook

12.1 Approved & Key CAR T Cell Therapy Products in Japan

12.2 Market Overview

12.3 Current Reimbursement Scenario

13. South Korea CAR T Cell Therapy Market Outlook

13.1 Approved & Key CAR T Cell Therapies in South Korea

13.2 Future Market Opportunity

14. Australia CAR T Cell Therapy Market Outlook

14.1 Approved & Key CAR T Cell Products in Australia

14.2 Australia CAR T Cell Therapy Market

14.3 Current Reimbursement Scenario

15. Taiwan CAR T Cell Therapy Market Outlook

16. Global CAR T Cells Clinical Pipeline Overview

16.1 By Company

16.2 By County

16.3 By Indication

16.4 By Phase

17. Global CAR T Cells Clinical Pipeline By Company, Indication & Phase

17.1 Research

17.2 Preclinical

17.3 Clinical

17.4 Phase-I

17.5 Phase-I/II

17.6 Phase-II

17.7 Phase-III

17.8 Registered

18. Marketed CAR T Cell Therapy Clinical insight

18.1 Breyanzi

18.2 CARVYKTI

18.3 Yescarta

18.4 Kymriah

18.5 Abecma

18.6 Tecartus

19. Global CAR-T Cell Therapy Market Dynamics

19.1 Favorable Parameters

19.2 Market Challenges

20. Competitive Landscape

20.1 Autolus

20.2 Bellicum

20.3 Bluebird

20.4 Celgene

20.5 Cellectis

20.6 Celyad

20.7 Eureka Therapeutics

20.8 Fortress Biotech

20.9 Immune Therapeutics

20.10 Juno Therapeutics

20.11 Kite Pharma

20.12 Novartis

20.13 Sorrento therapeutics

20.14 TILT Biotherapeutics

20.15 Ziopharm

  • Figure 2-1: Historical Development of CAR-T Cell Therapy
  • Figure 3-1: Structure of Chimeric Antigen Receptor
  • Figure 3-2: First Generation Chimeric Antigen Receptor
  • Figure 3-3: Second Generation Chimeric Antigen Receptor
  • Figure 3-4: Third Generation Chimeric Antigen Receptor
  • Figure 3-5: Targeting Mechanism of Chimeric Antigen Receptor T-Cell
  • Figure 3-6: Signalling Mechanism of Chimeric Antigen Receptor T-Cell
  • Figure 4-1: Strategies to Improve CAR T Cell Therapy
  • Figure 5-1: Flowchart for Manufacturing CAR T Cells
  • Figure 5-2: CAR T Cell - Annual Fixed Costs (US$)
  • Figure 5-3: CAR T Cell - Annual Fixed Costs (%)
  • Figure 5-4: CAR T Cell - Variable Cost Per Production (US$)
  • Figure 5-5: CAR T Cell - Variable Cost Per Production (%)
  • Figure 7-1: Global - Cancer Incidences & Deaths (Million), 2020
  • Figure 7-2: Global - CAR T Cell Therapy Market by Product (US$ Million), 2021
  • Figure 7-3: Global - CAR T Cell Therapy Market by Product (%), 2021
  • Figure 7-4: Global - CAR T Cell Therapy Market by Product (US$ Million), 2020
  • Figure 7-5: Global - CAR T Cell Therapy Market by Product (%), 2020
  • Figure 7-6: Global - CAR T Cell Therapy Market by Region (%), 2021
  • Figure 7-7: Global - CAR T Cell Therapy Market Size (US$ Billion), 2022 - 2028
  • Figure 8-1: US - Kymriah FDA Approval by Indication
  • Figure 8-2: Europe - Kymriah EMA Approval by Indication
  • Figure 8-3: Kymriah - Approval & Patent Exclusivity Year by Region
  • Figure 8-4: UK - Per Unit Price of Kymriah Infusion Bag (GBP/US$), May'2022
  • Figure 8-5: Kymriah - Per Unit Price of Intravenous Suspension by Region (US$), May'2022
  • Figure 8-6: Global - Kymriah Annual Sales (US$ Million), 2019 - 2021
  • Figure 8-7: Global - Kymriah Quarterly Sales (US$ Million), 2021
  • Figure 8-8: Global - Kymriah Quarterly Sales (US$ Million), 2020
  • Figure 8-9: Global - Kymriah Sales Forecast Value (US$ Million), 2022 - 2028
  • Figure 8-10: US - Yescarta FDA Approval by Indication
  • Figure 8-11: Yescarta - Approval Year by Region
  • Figure 8-12: US - Yescarta FDA Approval & Patent Expiration Year
  • Figure 8-13: UK - Per Unit Price of Yescarta Infusion Bag (GBP/US$), May'2022
  • Figure 8-14: Yescarta - Per Unit Price of Intravenous Suspension by Region (US$), May'2022
  • Figure 8-15: Yescarta - Global Sales by Region (US$ Million), Q1'2022
  • Figure 8-16: Yescarta - Global Sales by Region (%), Q1'2022
  • Figure 8-17: Global - Yescarta Annual Sales (US$ Million), 2018 - 2021
  • Figure 8-18: US - Yescarta Annual Sales (US$ Million), 2018 - 2021
  • Figure 8-19: Yescarta - Global Sales by Region (US$ Million), 2021
  • Figure 8-20: Yescarta - Global Sales by Region (%), 2021
  • Figure 8-21: Global - Yescarta Quarterly Sales (US$ Million), 2021
  • Figure 8-22: US - Yescarta Quarterly Sales (US$ Million), 2021
  • Figure 8-23: Europe - Yescarta Quarterly Sales (US$ Million), 2021
  • Figure 8-24: Global - Yescarta Quarterly Sales (US$ Million), 2020
  • Figure 8-25: Global - Yescarta Sales Forecast (US$ Million), 2022 - 2028
  • Figure 8-26: US - Yescarta Sales Forecast (US$ Million), 2022 - 2028
  • Figure 8-27: Europe - Yescarta Sales Forecast (US$ Million), 2022 - 2028
  • Figure 8-28: US - Tecartus FDA Approval by Indication
  • Figure 8-29: UK - Per Unit Price of Tecartus Infusion Bag (GBP/US$), May'2022
  • Figure 8-30: Tecartus - Per Unit Price of Intravenous Suspension by Region (US$), May'2022
  • Figure 8-31: Tecartus - Global Sales by Region (US$ Million), Q1'2022
  • Figure 8-32: Tecartus - Global Sale by Region (%), Q1'2022
  • Figure 8-33: Global - Tecartus Annual Sales (US$ Million), 2020 & 2021
  • Figure 8-34: US - Tecartus Annual Sales (US$ Million), 2020 & 2021
  • Figure 8-35: Tecartus - Global Sales by Region (US$ Million), 2021
  • Figure 8-36: Tecartus - Global Sales by Region (%), 2021
  • Figure 8-37: Global - Yescarta Quarterly Sales (US$ Million), 2021
  • Figure 8-38: US - Yescarta Quarterly Sales (US$ Million), 2021
  • Figure 8-39: Europe - Yescarta Quarterly Sales (US$ Million), 2021
  • Figure 8-40: Global - Tecartus Sales Forecast (US$ Million), 2022 - 2028
  • Figure 8-41: US - Tecartus Sales Forecast (US$ Million), 2022 - 2028
  • Figure 8-42: Breyanzi - Approval Year by Region
  • Figure 8-43: Breyanzi - Global Sales by Region (US$ Million), Q1'2022
  • Figure 8-44: Breyanzi - Global Sales by Region (%),Q1'2022
  • Figure 8-45: Global - Breyanzi Quarterly Sales (US$ Million), Q2-Q4'2021
  • Figure 8-46: Global - Breyanzi Sales Forecast (US$ Million), 2022 - 2028
  • Figure 8-47: US - Breyanzi Sales Forecast (US$ Million), 2022 - 2028
  • Figure 8-48: Abecma - Approval Year by Region
  • Figure 8-49: Abecma - Global Sales by Region (US$ Million), Q1'2022
  • Figure 8-50: Abecma - Global Sales by Region (%),Q1'2022
  • Figure 8-51: Abecma - Global Sales by Region (US$ Million), 2021
  • Figure 8-52: Abecma - Global Sales by Region (%), 2021
  • Figure 8-53: Global - Abecma Quarterly Sales (US$ Million), Q2-Q4'2021
  • Figure 8-54: US - Abecma Quarterly Sales (US$ Million), Q2-Q4'2021
  • Figure 8-55: Global - Abecma Sales Forecast (US$ Million), 2022 - 2028
  • Figure 8-56: US - Abecma Sales Forecast (US$ Million), 2022 - 2028
  • Figure 8-57: China - Carteyva Sales Forecast (US$ Million), 2022 - 2028
  • Figure 8-58: Global - Carvykti Sales Forecast (US$ Million), 2022 - 2028
  • Figure 9-1: US - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 9-2: US vs. ROW - CAR T Cell Therapy Market Size (US$ Million), 2021
  • Figure 9-3: US vs. ROW - CAR T Cell Therapy Market Size (%), 2021
  • Figure 9-4: US - CAR T Cell Therapy Market Size (US$ Million), 2022 - 2028
  • Figure 9-5: US - Cost of Drug & Total Cost of Treatment with CAR T Cell Therapy (US$), 2021
  • Figure 9-6: US - Cost of Single Infusion & Reimbursement Cost for Abecma & Breyanzi (US$)
  • Figure 9-7: US - Out of Pocket Cost & Reimbursement Cost for Abecma & Breyanzi (%)
  • Figure 10-1: UK - Cancer Incidences & Deaths, 2020 & 2025
  • Figure 10-2: UK vs. ROE - CAR T Cell Therapy Market Size (US$ Million), 2021
  • Figure 10-3: UK vs. ROE - CAR T Cell Therapy Market Size (%), 2021
  • Figure 10-4: UK - CAR T Cell Therapy Market Size (US$ Million), 2022 - 2028
  • Figure 10-5: Germany - Cancer Incidences & Deaths, 2020 & 2025
  • Figure 10-6: Germany vs. ROE - CAR T Cell Therapy Market Size (US$ Million), 2021
  • Figure 10-7: Germany vs. ROE - CAR T Cell Therapy Market Size (%), 2021
  • Figure 10-8: Germany - CAR T Cell Therapy Market Size (US$ Million), 2022 - 2028
  • Figure 10-9: Spain - Cancer Incidences & Deaths, 2020 & 2025
  • Figure 10-10: Spain vs. ROE - CAR T Cell Therapy Market Size (US$ Million), 2021
  • Figure 10-11: Spain vs. ROE - CAR T Cell Therapy Market Size (%), 2021
  • Figure 10-12: Spain - CAR T Cell Therapy Market Size (US$ Million), 2022 - 2028
  • Figure 10-13: France - Cancer Incidences & Deaths, 2020 & 2025
  • Figure 10-14: France vs. ROE - CAR T Cell Therapy Market Size (US$ Million), 2021
  • Figure 10-15: France vs. ROE - CAR T Cell Therapy Market Size (%), 2021
  • Figure 10-16: France - CAR T Cell Therapy Market Size (US$ Million), 2022 - 2028
  • Figure 10-17: Europe - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 10-18: Europe vs. ROW - CAR T Cell Therapy Market Size (US$ Million), 2021
  • Figure 10-19: Europe vs. ROW - CAR T Cell Therapy Market Size (%), 2021
  • Figure 10-20: Rest of Europe - CAR T Cell Therapy Market Size (US$ Million), 2022 - 2028
  • Figure 10-21: UK - Average Cost of Reimbursement with Kymriah & Yescarta per QALY (Euro/US$)
  • Figure 11-1: China - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 11-2: China - CAR T Clinical Trials by Phase'2020
  • Figure 11-3: China - Top 5 Pharmaceutical Companies Supporting CAR T Clinical Trials'2021
  • Figure 11-4: China - CAR T Cell Therapy Market Size (US$ Million), 2021 - 2028
  • Figure 12-1: Japan - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 12-2: Japan vs. ROW - CAR T Cell Therapy Market Size (US$ Million), 2021
  • Figure 12-3: Japan vs. ROW - CAR T Cell Therapy Market Size (%), 2021
  • Figure 12-4: Japan - CAR T Cell Therapy Market Size (US$ Million), 2022 - 2028
  • Figure 12-5: Japan - Current Retail & Reimbursed Price for Kymriah (JPY/US$), 2021
  • Figure 13-1: South Korea - Cancer Incidences & Deaths, 2020 & 2025
  • Figure 13-2: South Korea - CAR T Cell Therapy Market Size (US$ Million), 2021 - 2028
  • Figure 14-1: Australia - Cancer Incidences & Deaths, 2020 & 2025
  • Figure 14-2: Australia vs. ROW - CAR T Cell Therapy Market Size (US$ Million), 2021
  • Figure 14-3: Australia vs. ROW - CAR T Cell Therapy Market Size (%), 2021
  • Figure 14-4: Australia - CAR T Cell Therapy Market Size (US$ Million), 2022 - 2028
  • Figure 15-1: Taiwan - CAR T Cell Therapy Market Size (US$ Million), 2021 - 2028
  • Figure 16-1: Global - CAR T Cells Clinical Pipeline by Company, 2022 till 2028
  • Figure 16-2: Global - CAR T Cells Clinical Pipeline by Country, 2022 till 2028
  • Figure 16-3: Global - CAR T Cells Clinical Pipeline by Indication, 2022 till 2028
  • Figure 16-4: Global - CAR T Cells Clinical Pipeline by Phase, 2022 till 2028
  • Figure 19-1: Favorable Market Parameters of CAR T Cell Therapy
  • Figure 19-2: Challenges to Market Growth of CAR T Cell Therapy
  • Table 3-1: Antigens which are targeted by Chimeric Antigen Receptor
  • Table 5-1: CAR T Cell - Per Production Cost (US$)
  • Table 6-1: Advantage of VivoVec Platform over Traditional Platform
  • Table 6-2: ENLIGHTen - Phase I Trial Initiation & Completion Year
  • Table 9-1: US - FDA Approved CAR T Cell Therapy Products
  • Table 10-1: Europe - Approved CAR T Cell Therapy Products
  • Table 12-1: Japan - MHLW Approved CAR T Cell Therapy Products
  • Table 14-1: Australia -Approved CAR T Cell Therapy Products
  • Table 20-1: Clinical Pipelines of Products
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!